Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Even I added some this morning
I really don't know, but this is typical sp action following a short attack and weak hands dumping their shares out of fear. The savvy investors wait for it to hit bottom, which I believe it did this morning, and then jump in and ride it back up. Sadly, many people miss the ride back up and then spend the next few months wishing they increased their shares when they had the chance. There are too many catalysts in the near term that could trigger a massive jump overnight, so enjoy the ride up.
I expect to see more days like this in the near term.
Being up 15% is more than a little bump. This is typical prior to large run up. This is the time when many investors will take advantage of the low sp.
Think this little bump will collapse?
I want to say it will be closer to $10 in 6 months
Harish Seethamraju, M.D., Medical Director for the Mount Sinai Lung Transplantation Program, commented, “The CD12 trial results are very promising and leronlimab may be the only safe medication to help critically ill patients.”
In my opinion (and Dr Seethamraju's), this says it all. Clearly the medical community interprets the CD12 results as "very promising", and I doubt the FDA sees it differently.
For the shorts, I guess you can say it's stuck above $4.
CYDY stuck below $5?
It is not known that is is effective. For a good reason: Leronlimab is not effective.
Also, the FDA is not responsible for any delay. Cytodyn is.
It's a fraud whose only objective is to enrich its insiders at the expense of external shareholders.
This is the first time in biotech/BP history that a company has submitted their data to the FDA (in this case, multiple FDAs) to ask for approval BEFORE announcing success of an endpoint. Look at the previous vaccines and MABs that have been approved for COVID: they announced efficacy first and then that they’d apply for EUA. If the primary endpoint had been met, CYDY would’ve PRed it.
Well it’s pretty obvious this is great news.
Up 10%...
Just hit $6
The smart ones are getting out...
Uh oh, shorts might be going into panic mode.
Heading back to $6. Makes me wonder if we're going to get a PR after the close.
What's up with the sp? Just hit $5.75 and steady climbing...
Please share with the group where they lied about their partnership.
The partnership is still intact. It was no lie - anyone can do a search and find it. Are you suggesting they lied about the partnership? lol
Where is this partnership these days? The revenue for it? NADER/KELLY lie consistently and then deny they said anything. It is not hard to get your SP up when you lie and mislead shareholders.
Your post confirms the shorts thesis here. Pump and Dump
I agree, it will be game over -- for the shorts. You probably weren't here a little over a year ago in Dec, 2019 when NP announced a conference call when everyone had been waiting for an announcement on a partnership. Some started yelling about how NP lied and there was no deal, and some foolishly sold some or all of their shares because they were convinced having a conference call had to be bad news. And what happened? He announced the deal with Vyera, and the stock quadrupled over the next couple of days while leaving the shorts chasing the sp while trying to cover their shares. And those who sold and weren't shorts, had to buy back in at a much higher premium. But I'm sure NP would never do that again.
If we get a PR about a call next week to discuss the fantastic meaningful results it is game over.
Anyone who flipped and sold when this was in the $5 range last week is in trouble, in my opinion.
Same here. I am up 12X in less than five years. That is better than Bezos has done!!
Those who bash in NP haven’t made as much money as they would have you think they have
Thanks to the shorts, the float is now 30mm shares smaller...
And factor in that so many longs are holding on to their shares for the big binary announcements, I would guess the float is much smaller now, setting up the shorts for the perfect storm.
So paying with shares is not paying down their debt??? ROFLMAO
Bankruptcy??? ROFLMAO Only you can answer that, but I suspect it will be sometime next week after the margin call.
PAYING??? Theyre not paying with money, theyre offering SHARES.
LOL
Whens the bankruptcy filing?
Oh, so there was no benefit of paying down their debt. My bad...
You can spin it however you like, but clearly CYDY just paid down some of the debt they owed Fife which reduces their overall debt and increases their shareholder equity.
I think you missed the point. CYDY just paid down some of the debt they owed Fife which reduces their overall debt and increases their shareholder equity. This is required for uplisting to NASDAQ and is a step in that direction. Looks like they're getting their ducks in a row for the big announcement. That's the real takeaway from the S-3, and it looks like I'll be sleeping much better tonight than the shorts.
LOL - why would CYDY get the proceeds from the shares that he's selling??? Fife doesn't owe CYDY the proceeds?
LMAO!
We will not receive any proceeds from the sale of shares of our common stock by the selling stockholder.
I think we're all laughing at the shorts because they clearly don't understand the S-3 Registration. CYDY just paid down some of the debt they owed Fife which reduces their debt and increases their shareholder equity. This is required for uplisting to NASDAQ and is a step in that direction. Looks like they're getting their ducks in a row for the big announcement.
Thanks Tom!
Yeah, it's up over 100% in just two weeks. What a horrible investment! Very depressing...
down she goes folks I feel bad for all the people who are getting depressed over this horrible investment.
No, this is Justdafud L. Oser and he has no relationship to CYDY.
Wait till the news gets out today. We're in for a wild ride up IMO.
I suspect the MMs are holding it down so the shorts can get out - shouldn't last long.
In all treated patients, at the End of Treatment (or Day 14), patients in the leronlimab group were more than twice as likely to experience a beneficial improvement in scores compared to patients in the placebo group (50% vs 20%; p=0.0223).
CytoDyn Announces Clinically Significant Top-line Results from its Phase 2 Trial in Mild-to-Moderate COVID-19 Patients
Primary endpoint shows early clinical improvement in symptom score at Day 3 in patients receiving leronlimab
Leronlimab also demonstrated statistically significant improvement versus placebo in key secondary efficacy endpoint, National Early Warning Score 2 scale (NEWS2)
Results will be reported to the United States FDA, United Kingdom MHRA, and European Union regulatory agency, EMA
Management to hold conference call on August 12 at 1:00 pm PT - - details to follow
VANCOUVER, Washington, Aug. 11, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company announced today the Top-line results from its recently completed, randomized, double-blind, Phase 2 trial for COVID-19 patients with mild-to-moderate symptoms. CytoDyn will submit its Top-line Report for this trial to the U.S. Food and Drug Administration for review later this week. The Top-line Report revealed the following information:
Clinical improvement assessed by change in total clinical symptom score:
In patients with Total Clinical Symptom Score of ≥ 4 at baseline (higher scores equate to poorer health state): At Day 3, more subjects treated with leronlimab reported improvement in total clinical symptom score compared to the placebo group (90% on leronlimab arm vs. 71% on placebo). The subgroup analysis indicates that among patients with more symptoms at baseline, those who received leronlimab had a greater treatment effect than patients who received the placebo.
The National Early Warning Score 2 (NEWS2):
The National Early Warning Score (NEWS) is an objective scale developed by the Royal College of Physicians to identify patients at risk for rapid clinical deterioration requiring critical care intervention. NEWS2 (the latest version), is being used as an endpoint in several other COVID-19 clinical trials, including CytoDyn's severe-to-critical COVID-19 Phase 3 trial. It measures clinical parameters including respiratory rate, oxygen saturation, supplemental oxygen, temperature, systolic blood pressure, heart rate, and level of consciousness. In all treated patients, at the End of Treatment (or Day 14), patients in the leronlimab group were more than twice as likely to experience a beneficial improvement in scores compared to patients in the placebo group (50% vs 20%; p=0.0223).
Similar, statistically significant, results were observed at Day 3 and Day 14 in the analysis of per protocol population (p<0.03 and p<0.02, respectively).
Safety Endpoints:
The incidence, frequency, and severity of adverse events (AEs) and serious adverse events (SAEs) were lower in the leronlimab group compared to the placebo group. Patients treated with placebo were more than twice as likely to experience SAEs or AEs compared to patients treated with leronlimab.
Harish Seethamraju, M.D., Lead Principal Investigator at Montefiore Medical Center NY, stated, “The results demonstrate that CCR5 blockade by leronlimab given as a weekly subcutaneous injection in mild-to-moderate COVID-19 patients is reasonably safe and associated with rapid improvement in viral symptoms with fewer adverse events than when compared to placebo.”
Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, stated, “In the mild- to-moderate population, it is important to have a therapeutic option for COVID-19 in patients who are showing signs of rapid clinical deterioration. Patients receiving leronlimab showed a statistically significant improvement using NEWS2 clinical parameters. We will make a case for immediate approval of leronlimab for this population of COVID-19 patients, not only in the U.S., but in the U.K. and other countries around the world.”
Scott A. Kelly, M.D., Chief Medical Officer of CytoDyn, said, “We are thrilled with the results of leronlimab in mild-to-moderate COVID-19 patients. It is paramount to determine which patients will deteriorate and require critical care interventions, including patients at risk for ICU admission, cardiac arrest, or death within 24 hours. The NEWS2 aims to identify those patients most at risk. We are pleased that leronlimab showed a statistically significant result in a randomized, double-blinded study for NEWS2. The decreased probability in serious adverse events, as well as overall adverse events with leronlimab compared to placebo further supports the use of leronlimab as a treatment option for COVID-19.”
Jacob P. Lalezari, M.D., Senior Science Advisor to CytoDyn, said, "Treatment with leronlimab demonstrated reductions in both serious adverse events, as well as predictors of pulmonary collapse in patients with mild-to-moderate COVID-19. We initiated the study hoping to reduce flu-like symptoms, such as fever, cough, and muscle aches. In the end, use of leronlimab was not only correlated with improved symptom scores in patients with measurable symptoms at baseline, but also provided significant and consequential benefits on far more serious endpoints. Demonstrating these efficacy signals in a population with mostly mild illness at study entry bodes well for leronlimab’s activity in patients with more severe illness.”
Transcript of yesterday's call for those who haven't seen it:
https://www.transcriptshare.com/s/cydy/cytodyn-covid-update-july-30
The funny thing is this has nothing to do with tomorrow's call about the Covid updates. I think they just dropped this PR due to today's shorting and probably wanted to give them something to think about for the next 15 hours. LOL
I know I'll sleep good tonight!
That's true for those who haven't shorted yet, but for those who have, they need to cover now before the sp goes up. Otherwise, they may get margin calls, especially if it's very good news and goes up quickly. The sp is being held below $5 for a reason.
I would think the "shorts" would want the PPS to run before shorting.
Yeah, I thought there was one time they did that, and I now remember that one. But I'm willing to bet there aren't any other times when they PR'd a major announcement before the call.
Can you give me an example of when they did this? I've been here for over four years and don't recall ever seeing them drop a PR announcing major news BEFORE the conference call. They usually have the call, announce the major news, and then follow up with a PR after the call or prior to the opening bell the next day. For an example, look at how they made the licensing deal announcement on Dec 17.
"In the past when we have had major events it was a first thing in the morning PR, one that's detailed and a conference call within a day of the major news."
Thanks Tom! I always look forward to your TA posts.
They don't need to schedule a call with 45 minutes of Q&A to tell us that.